{"id":"https://openalex.org/W4398763263","doi":"https://doi.org/10.1021/acs.jmedchem.4c00856","title":"Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists","display_name":"Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists","alternate_titles":[],"publication_year":2024,"publication_date":"2024-05-24","ids":{"openalex":"https://openalex.org/W4398763263","doi":"https://doi.org/10.1021/acs.jmedchem.4c00856","pmid":"https://pubmed.ncbi.nlm.nih.gov/38788241","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11441106"},"language":"en","primary_location":{"id":"doi:10.1021/acs.jmedchem.4c00856","doi":"https://doi.org/10.1021/acs.jmedchem.4c00856","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.jmedchem.4c00856","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4398763263"],"child_works_count":6,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/661dba1b91aefa6ce1a3c46f/original/discovery-of-3-4-benzylpyridin-2-yl-amino-benzamide-derivatives-as-potent-gpr52-g-protein-biased-agonists.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085609032","display_name":"Ryan E. Murphy","orcid":"https://orcid.org/0000-0003-0771-8800","observed_orcids":["https://orcid.org/0000-0003-0771-8800"]},"institutions":[{"id":"https://openalex.org/I55302922","display_name":"The University of Texas Medical Branch at Galveston","ror":"https://ror.org/016tfm930","country_code":"US","type":"education","lineage":["https://openalex.org/I55302922"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan E. Murphy","raw_affiliation_strings":["Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States"],"raw_orcid":"https://orcid.org/0000-0003-0771-8800","affiliations":[{"raw_affiliation_string":"Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States","institution_ids":["https://openalex.org/I55302922"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045620483","display_name":"Pingyuan Wang","orcid":"https://orcid.org/0009-0005-0368-5070","observed_orcids":["https://orcid.org/0009-0005-0368-5070"]},"institutions":[{"id":"https://openalex.org/I55302922","display_name":"The University of Texas Medical Branch at Galveston","ror":"https://ror.org/016tfm930","country_code":"US","type":"education","lineage":["https://openalex.org/I55302922"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pingyuan Wang","raw_affiliation_strings":["Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States"],"raw_orcid":"https://orcid.org/0009-0005-0368-5070","affiliations":[{"raw_affiliation_string":"Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States","institution_ids":["https://openalex.org/I55302922"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030701824","display_name":"Saghir Ali","orcid":"https://orcid.org/0000-0002-7400-5512","observed_orcids":["https://orcid.org/0000-0002-7400-5512"]},"institutions":[{"id":"https://openalex.org/I55302922","display_name":"The University of Texas Medical Branch at Galveston","ror":"https://ror.org/016tfm930","country_code":"US","type":"education","lineage":["https://openalex.org/I55302922"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Saghir Ali","raw_affiliation_strings":["Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States","institution_ids":["https://openalex.org/I55302922"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039008777","display_name":"Hudson R. Smith","orcid":"https://orcid.org/0000-0002-0347-0855","observed_orcids":["https://orcid.org/0000-0002-0347-0855"]},"institutions":[{"id":"https://openalex.org/I55302922","display_name":"The University of Texas Medical Branch at Galveston","ror":"https://ror.org/016tfm930","country_code":"US","type":"education","lineage":["https://openalex.org/I55302922"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hudson R. Smith","raw_affiliation_strings":["Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States","institution_ids":["https://openalex.org/I55302922"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074769127","display_name":"Daniel Eric Felsing","orcid":"https://orcid.org/0000-0002-4039-2227","observed_orcids":["https://orcid.org/0000-0002-4039-2227"]},"institutions":[{"id":"https://openalex.org/I55302922","display_name":"The University of Texas Medical Branch at Galveston","ror":"https://ror.org/016tfm930","country_code":"US","type":"education","lineage":["https://openalex.org/I55302922"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel E. Felsing","raw_affiliation_strings":["Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States","institution_ids":["https://openalex.org/I55302922"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100637456","display_name":"Haiying Chen","orcid":"https://orcid.org/0000-0003-2841-5518","observed_orcids":["https://orcid.org/0000-0003-2841-5518"]},"institutions":[{"id":"https://openalex.org/I55302922","display_name":"The University of Texas Medical Branch at Galveston","ror":"https://ror.org/016tfm930","country_code":"US","type":"education","lineage":["https://openalex.org/I55302922"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haiying Chen","raw_affiliation_strings":["Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States","institution_ids":["https://openalex.org/I55302922"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023901418","display_name":"Jia Zhou","orcid":"https://orcid.org/0000-0002-2811-1090","observed_orcids":["https://orcid.org/0000-0002-2811-1090"]},"institutions":[{"id":"https://openalex.org/I55302922","display_name":"The University of Texas Medical Branch at Galveston","ror":"https://ror.org/016tfm930","country_code":"US","type":"education","lineage":["https://openalex.org/I55302922"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jia Zhou","raw_affiliation_strings":["Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States"],"raw_orcid":"https://orcid.org/0000-0002-2811-1090","affiliations":[{"raw_affiliation_string":"Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States","institution_ids":["https://openalex.org/I55302922"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070959736","display_name":"John Allen","orcid":"https://orcid.org/0000-0002-6205-3031","observed_orcids":["https://orcid.org/0000-0002-6205-3031"]},"institutions":[{"id":"https://openalex.org/I55302922","display_name":"The University of Texas Medical Branch at Galveston","ror":"https://ror.org/016tfm930","country_code":"US","type":"education","lineage":["https://openalex.org/I55302922"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"John A. Allen","raw_affiliation_strings":["Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Addiction Sciences and Therapeutics, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States","institution_ids":["https://openalex.org/I55302922"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5023901418","https://openalex.org/A5070959736"],"corresponding_institution_ids":["https://openalex.org/I55302922"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.8173,"has_fulltext":true,"cited_by_count":8,"citation_normalized_percentile":{"value":0.65055259,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"67","issue":"11","first_page":"9709","last_page":"9730"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.9042999744415283,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.9042999744415283,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10414","display_name":"Cannabis and Cannabinoid Research","score":0.022700000554323196,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.016699999570846558,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gpr52","display_name":"GPR52","score":0.9990000128746033},{"id":"https://openalex.org/keywords/orphan-gpcrs","display_name":"orphan G protein-coupled receptor","score":0.8330000042915344},{"id":"https://openalex.org/keywords/biased-agonists","display_name":"biased agonists","score":0.6899999976158142},{"id":"https://openalex.org/keywords/benzamide","display_name":"benzamide","score":0.7699999809265137},{"id":"https://openalex.org/keywords/g-protein-signaling","display_name":"G protein signaling","score":0.6949999928474426},{"id":"https://openalex.org/keywords/camp-signaling","display_name":"cAMP signaling","score":0.7979999780654907},{"id":"https://openalex.org/keywords/beta-arrestin","display_name":"beta-arrestin","score":0.781000018119812},{"id":"https://openalex.org/keywords/receptor-desensitization","display_name":"receptor desensitization","score":0.9549999833106995},{"id":"https://openalex.org/keywords/brain-exposure","display_name":"brain exposure","score":0.6589999794960022}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.9465072154998779},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5024042129516602},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.37566354870796204},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D043562","descriptor_name":"Receptors, G-Protein-Coupled","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D043562","descriptor_name":"Receptors, G-Protein-Coupled","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057809","descriptor_name":"HEK293 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1021/acs.jmedchem.4c00856","doi":"https://doi.org/10.1021/acs.jmedchem.4c00856","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.jmedchem.4c00856","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"doi:10.26434/chemrxiv-2024-5kzm8","doi":"https://doi.org/10.26434/chemrxiv-2024-5kzm8","is_oa":true,"landing_page_url":"https://doi.org/10.26434/chemrxiv-2024-5kzm8","pdf_url":"https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/661dba1b91aefa6ce1a3c46f/original/discovery-of-3-4-benzylpyridin-2-yl-amino-benzamide-derivatives-as-potent-gpr52-g-protein-biased-agonists.pdf","source":{"id":"https://openalex.org/S4393918830","display_name":"ChemRxiv","issn_l":"2573-2293","issn":["2573-2293"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},{"id":"pmid:38788241","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38788241","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11441106","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11441106","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11441106/pdf/nihms-2023639.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"J Med Chem","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.26434/chemrxiv-2024-5kzm8","doi":"https://doi.org/10.26434/chemrxiv-2024-5kzm8","is_oa":true,"landing_page_url":"https://doi.org/10.26434/chemrxiv-2024-5kzm8","pdf_url":"https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/661dba1b91aefa6ce1a3c46f/original/discovery-of-3-4-benzylpyridin-2-yl-amino-benzamide-derivatives-as-potent-gpr52-g-protein-biased-agonists.pdf","source":{"id":"https://openalex.org/S4393918830","display_name":"ChemRxiv","issn_l":"2573-2293","issn":["2573-2293"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8048999905586243}],"study_designs":[],"awards":[{"id":"https://openalex.org/G6963141084","display_name":"Validation of GPR52 agonists as a therapeutic approach for stimulant use disorders","funder_award_id":"U18DA052543","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G9000865442","display_name":"Translational Explorations in Substance Use Disorders","funder_award_id":"T32DA007287","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320306799","display_name":"Pharmaceutical Research and Manufacturers of America Foundation","ror":"https://ror.org/01z88k350"},{"id":"https://openalex.org/F4320310135","display_name":"University of Texas Medical Branch","ror":"https://ror.org/016tfm930"},{"id":"https://openalex.org/F4320332600","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33"},{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4398763263.pdf","grobid_xml":"https://content.openalex.org/works/W4398763263.grobid-xml"},"referenced_works_count":54,"referenced_works":["https://openalex.org/W1977183929","https://openalex.org/W1977323674","https://openalex.org/W1983435506","https://openalex.org/W1991001144","https://openalex.org/W2001626986","https://openalex.org/W2013971421","https://openalex.org/W2034475831","https://openalex.org/W2036251618","https://openalex.org/W2060207881","https://openalex.org/W2121473111","https://openalex.org/W2130632774","https://openalex.org/W2135319033","https://openalex.org/W2147196684","https://openalex.org/W2157606687","https://openalex.org/W2167021628","https://openalex.org/W2191622804","https://openalex.org/W2257290296","https://openalex.org/W2288077045","https://openalex.org/W2328001213","https://openalex.org/W2581696375","https://openalex.org/W2603126041","https://openalex.org/W2611645197","https://openalex.org/W2626714978","https://openalex.org/W2730889053","https://openalex.org/W2752150260","https://openalex.org/W2770319189","https://openalex.org/W2777388159","https://openalex.org/W2780167836","https://openalex.org/W2787051453","https://openalex.org/W2790021741","https://openalex.org/W2792983781","https://openalex.org/W2794666635","https://openalex.org/W2799218365","https://openalex.org/W2805951153","https://openalex.org/W2905480784","https://openalex.org/W2973071485","https://openalex.org/W3007690345","https://openalex.org/W3007954652","https://openalex.org/W3014691264","https://openalex.org/W3033558299","https://openalex.org/W3098874711","https://openalex.org/W3100284523","https://openalex.org/W3169415458","https://openalex.org/W3216763196","https://openalex.org/W4210732285","https://openalex.org/W4324132996","https://openalex.org/W4362705893","https://openalex.org/W4363624525","https://openalex.org/W4376604801","https://openalex.org/W4383371925","https://openalex.org/W4386496978","https://openalex.org/W4386991618","https://openalex.org/W4391951817","https://openalex.org/W4392517685"],"related_works":["https://openalex.org/W4225400616","https://openalex.org/W3100284523","https://openalex.org/W2603126041","https://openalex.org/W3171333053","https://openalex.org/W2328001213","https://openalex.org/W4396849975","https://openalex.org/W2790021741","https://openalex.org/W7162483998","https://openalex.org/W4391951817","https://openalex.org/W7125713122"],"abstract_inverted_index":{"Orphan":[0],"GPR52":[1,30,78,87,116,124],"is":[2],"emerging":[3],"as":[4,33],"a":[5,26],"promising":[6],"neurotherapeutic":[7],"target.":[8],"Optimization":[9],"of":[10,25,28,91],"previously":[11],"reported":[12],"lead":[13],"4a":[14],"employing":[15],"an":[16],"iterative":[17],"drug":[18],"design":[19],"strategy":[20],"led":[21],"to":[22,122],"the":[23],"identification":[24],"series":[27],"unique":[29],"agonists,":[31],"such":[32],"10a":[34,54],"(":[35,39,44],"PW0677":[36],"),":[37,41,46],"15b":[38,93],"PW0729":[40],"and":[42,50,55,64,94,99,101,114,128,133],"24f":[43,56,95],"PW0866":[45],"with":[47,81],"improved":[48,97],"potency":[49,98],"efficacy.":[51],"Intriguingly,":[52],"compounds":[53,92],"showed":[57],"greater":[58],"bias":[59],"for":[60,131],"G":[61],"protein/cAMP":[62],"signaling":[63,126],"induced":[65],"significantly":[66],"less":[67],"in":[68,85],"vitro":[69],"desensitization":[70],"than":[71],"parent":[72],"compound":[73],"4a,":[74],"indicating":[75],"that":[76],"reducing":[77],"\u03b2-arrestin":[79],"activity":[80],"biased":[82,115],"agonism":[83],"results":[84],"sustained":[86],"activation.":[88],"Further":[89],"exploration":[90],"indicated":[96],"efficacy,":[100],"excellent":[102],"target":[103],"selectivity,":[104],"but":[105],"limited":[106],"brain":[107],"exposure":[108],"warranting":[109],"further":[110],"optimization.":[111],"These":[112],"balanced":[113],"agonists":[117],"provide":[118],"important":[119],"pharmacological":[120],"tools":[121],"study":[123],"activation,":[125],"bias,":[127],"therapeutic":[129],"potential":[130],"neuropsychiatric":[132],"neurological":[134],"diseases.":[135]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4398763263","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-15T12:55:33.944570","created_date":"2024-05-25T00:00:00"}
